These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 36948869)

  • 41. The Chronic Kidney Disease Epidemiology Collaboration cystatin C (CKD-EPI-CysC) equation has an independent prognostic value for overall survival in newly diagnosed patients with symptomatic multiple myeloma; is it time to change from MDRD to CKD-EPI-CysC equations?
    Terpos E; Christoulas D; Kastritis E; Katodritou E; Pouli A; Michalis E; Papassotiriou I; Dimopoulos MA;
    Eur J Haematol; 2013 Oct; 91(4):347-55. PubMed ID: 23829647
    [TBL] [Abstract][Full Text] [Related]  

  • 42. VMP (Bortezomib, Melphalan, and Prednisone) is active and well tolerated in newly diagnosed patients with multiple myeloma with moderately impaired renal function, and results in reversal of renal impairment: cohort analysis of the phase III VISTA study.
    Dimopoulos MA; Richardson PG; Schlag R; Khuageva NK; Shpilberg O; Kastritis E; Kropff M; Petrucci MT; Delforge M; Alexeeva J; Schots R; Masszi T; Mateos MV; Deraedt W; Liu K; Cakana A; van de Velde H; San Miguel JF
    J Clin Oncol; 2009 Dec; 27(36):6086-93. PubMed ID: 19858394
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Carfilzomib vs bortezomib in patients with multiple myeloma and renal failure: a subgroup analysis of ENDEAVOR.
    Dimopoulos M; Siegel D; White DJ; Boccia R; Iskander KS; Yang Z; Kimball AS; Mezzi K; Ludwig H; Niesvizky R
    Blood; 2019 Jan; 133(2):147-155. PubMed ID: 30478094
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Treatment Regimens for Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: A Systematic Literature Review and Network Meta-analysis.
    Facon T; San-Miguel J; Dimopoulos MA; Mateos MV; Cavo M; van Beekhuizen S; Yuan Z; Mendes J; Lam A; He J; Ammann E; Kumar S
    Adv Ther; 2022 May; 39(5):1976-1992. PubMed ID: 35246820
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Daratumumab Improves Depth of Response and Progression-free Survival in Transplant-ineligible, High-risk, Newly Diagnosed Multiple Myeloma.
    Jakubowiak AJ; Kumar S; Medhekar R; Pei H; Lefebvre P; Kaila S; He J; Lafeuille MH; Cortoos A; Londhe A; Mavros P; Lin TS; Usmani SZ
    Oncologist; 2022 Jul; 27(7):e589-e596. PubMed ID: 35462406
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Renal Impairment at Diagnosis in Myeloma: Patient Characteristics, Treatment, and Impact on Outcomes. Results From the Australia and New Zealand Myeloma and Related Diseases Registry.
    Ho PJ; Moore EM; McQuilten ZK; Wellard C; Bergin K; Augustson B; Blacklock H; Harrison SJ; Horvath N; King T; Mollee P; Quach H; Reid C; Rosengarten B; Walker P; Wood EM; Spencer A
    Clin Lymphoma Myeloma Leuk; 2019 Aug; 19(8):e415-e424. PubMed ID: 31208889
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Clinical characteristics and prognostic values of 1p32.3 deletion detected through fluorescence in situ hybridization in patients with newly diagnosed multiple myeloma: a single-center study in China.
    Wang H; Meng H; Wang J; Lou Y; Zhou Y; Lin P; Li F; Liu L; Xu H; Yang M; Jin J
    Front Med; 2020 Jun; 14(3):327-334. PubMed ID: 31784918
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A Report of 134 Newly Diagnosed Multiple Myeloma Patients with Renal Impairment.
    Liu A; Yang G; Geng C; Wang H; Li L; Li Y; Wu Y; Tian Y; Leng Y; Wang G; Gao W; Chen W
    Acta Haematol; 2016; 135(3):140-5. PubMed ID: 26587903
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Ixazomib-based regimens for relapsed/refractory multiple myeloma: are real-world data compatible with clinical trial outcomes? A multi-site Israeli registry study.
    Cohen YC; Magen H; Lavi N; Gatt ME; Chubar E; Horowitz N; Kreiniz N; Tadmor T; Trestman S; Vitkon R; Rouvio O; Shvetz O; Shaulov A; Ziv-Baran T; Avivi I
    Ann Hematol; 2020 Jun; 99(6):1273-1281. PubMed ID: 32193630
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Gain of 1q21 is an adverse prognostic factor for multiple myeloma patients treated by autologous stem cell transplantation: A multicenter study in China.
    Gao W; Jian Y; Du J; Li X; Zhou H; Zhang Z; Yang G; Wang G; Tian Y; Li Y; Wu Y; Fu W; Li J; Chen W
    Cancer Med; 2020 Nov; 9(21):7819-7829. PubMed ID: 32881351
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Clinical Efficacy and Prognosis of Double-Hit Multiple Myeloma Patients with Deletion P53 Treated with Regimen Based on Bortezomib].
    Wang DM; Chen YY; Meng Z; Zhang YX; Guo SQ; Li YH
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Aug; 28(4):1221-1227. PubMed ID: 32798402
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Clinical features and treatment outcome of elderly multiple myeloma patients with impaired renal function.
    Chen J; Liu H; Li L; Liu Z; Song J; Wang G; Wang H; Ruan E; Ding K; Shao Z; Fu R
    J Clin Lab Anal; 2019 Jun; 33(5):e22888. PubMed ID: 31004381
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The paradoxical prognostic role of 1q21 Gain/Amplification in multiple myeloma: every coin has two sides.
    Xu J; Xu T; Yang Y; Wang W; Li J; Ren Y; Gu S; Chen C; Wei Z; Zhuang J; Wang Z; Ji L; Cheng L; Wang W; Cheng Z; Ke Y; Yuan L; Liu P
    Leuk Lymphoma; 2020 Oct; 61(10):2351-2364. PubMed ID: 32519901
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Frailty Subgroup Analysis of ALCYONE.
    Mateos MV; Dimopoulos MA; Cavo M; Suzuki K; Knop S; Doyen C; Lucio P; Nagy Z; Pour L; Grosicki S; Crepaldi A; Liberati AM; Campbell P; Yoon SS; Iosava G; Fujisaki T; Garg M; Iida S; Bladé J; Ukropec J; Pei H; Van Rampelbergh R; Kudva A; Qi M; San-Miguel J
    Clin Lymphoma Myeloma Leuk; 2021 Nov; 21(11):785-798. PubMed ID: 34344638
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Impact of quality of response on survival outcomes among multiple myeloma patients treated with novel agents - a retrospective analysis.
    Ćojbašić I; Vučić M; Tijanić I; Ćojbašić Ž
    Sao Paulo Med J; 2022; 140(2):222-228. PubMed ID: 35195237
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [The Efficacy and Safety of Daratumumab-Based Regimen in Treatment of Multiple Myeloma Patients with Renal Impairment].
    Yin LL; Shen YL; Min FL; Gu WY; Wang Y; Qi KM; Li ZY; Xu KL
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Feb; 31(1):141-147. PubMed ID: 36765491
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Ixazomib combined with lenalidomide and dexamethasone chemotherapy for newly diagnosed multiple myeloma in China-Compared with bortezomib/lenalidomide/dexamethasone.
    Huo Z; Chen F; Liu P; Luo Z
    Cancer Med; 2023 Feb; 12(3):2937-2944. PubMed ID: 36052569
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Analysis of clinical features, treatment response, and prognosis among 61 elderly newly diagnosed multiple myeloma patients: a single-center report.
    An N; Li X; Shen M; Chen S; Huang Z
    World J Surg Oncol; 2015 Aug; 13():239. PubMed ID: 26245342
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Gain of 1q21 is an unfavorable genetic prognostic factor for multiple myeloma patients treated with high-dose chemotherapy.
    Nemec P; Zemanova Z; Greslikova H; Michalova K; Filkova H; Tajtlova J; Kralova D; Kupska R; Smetana J; Krejci M; Pour L; Zahradova L; Sandecka V; Adam Z; Buchler T; Spicka I; Gregora E; Kuglik P; Hajek R
    Biol Blood Marrow Transplant; 2010 Apr; 16(4):548-54. PubMed ID: 20005965
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Evaluation of the frailty characteristics and clinical outcomes according to the new frailty-based outcome prediction model (Myeloma Risk Profile-MRP) in a UK real-world cohort of elderly newly diagnosed Myeloma patients.
    Djebbari F; Rampotas A; Panitsas F; Lim WY; Lees C; Tsagkaraki I; Gomes AR; Prideaux S; Chen L; Prodger C; Khera A; Gray N; Ellis L; Sangha G; Eyre TA; Moore S; Kothari J; Ramasamy K
    PLoS One; 2022; 17(1):e0262388. PubMed ID: 35015781
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.